AR085724A1 - ANALOGO DE LA SANGLIFERINA CON ACTIVIDAD INHIBIDORA DE mPTP - Google Patents

ANALOGO DE LA SANGLIFERINA CON ACTIVIDAD INHIBIDORA DE mPTP

Info

Publication number
AR085724A1
AR085724A1 ARP120101043A ARP120101043A AR085724A1 AR 085724 A1 AR085724 A1 AR 085724A1 AR P120101043 A ARP120101043 A AR P120101043A AR P120101043 A ARP120101043 A AR P120101043A AR 085724 A1 AR085724 A1 AR 085724A1
Authority
AR
Argentina
Prior art keywords
sangliferina
mptp
analog
inhibiting activity
compound
Prior art date
Application number
ARP120101043A
Other languages
English (en)
Spanish (es)
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105293.3A external-priority patent/GB201105293D0/en
Priority claimed from GBGB1113629.8A external-priority patent/GB201113629D0/en
Priority claimed from GBGB1202060.8A external-priority patent/GB201202060D0/en
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of AR085724A1 publication Critical patent/AR085724A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/061,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
ARP120101043A 2011-03-29 2012-03-28 ANALOGO DE LA SANGLIFERINA CON ACTIVIDAD INHIBIDORA DE mPTP AR085724A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1105293.3A GB201105293D0 (en) 2011-03-29 2011-03-29 Novel compounds and methods for their production
GBGB1113629.8A GB201113629D0 (en) 2011-08-08 2011-08-08 Novel compounds and methods for their production
GBGB1202060.8A GB201202060D0 (en) 2012-02-07 2012-02-07 Novel compounds and methods for their production

Publications (1)

Publication Number Publication Date
AR085724A1 true AR085724A1 (es) 2013-10-23

Family

ID=46001313

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101043A AR085724A1 (es) 2011-03-29 2012-03-28 ANALOGO DE LA SANGLIFERINA CON ACTIVIDAD INHIBIDORA DE mPTP

Country Status (29)

Country Link
US (2) US9090657B2 (ru)
EP (2) EP2691413B1 (ru)
JP (2) JP6118793B2 (ru)
KR (2) KR101911484B1 (ru)
CN (3) CN103619869B (ru)
AR (1) AR085724A1 (ru)
AU (2) AU2012235880B2 (ru)
BR (2) BR112013024974A2 (ru)
CA (2) CA2830831C (ru)
CL (2) CL2013002739A1 (ru)
CY (2) CY1116318T1 (ru)
DK (2) DK2691412T3 (ru)
EA (2) EA023848B1 (ru)
ES (2) ES2533437T3 (ru)
HK (2) HK1189236A1 (ru)
HR (2) HRP20150184T1 (ru)
IL (2) IL228509B (ru)
JO (1) JO3063B1 (ru)
MX (2) MX345351B (ru)
MY (2) MY170637A (ru)
PL (2) PL2691413T3 (ru)
PT (2) PT2691412E (ru)
RS (2) RS53964B1 (ru)
SG (2) SG193568A1 (ru)
SI (2) SI2691413T1 (ru)
TW (1) TWI525098B (ru)
UY (1) UY33993A (ru)
WO (2) WO2012131371A1 (ru)
ZA (2) ZA201307149B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012019866A8 (pt) 2010-02-09 2017-12-26 Biotica Tech Limited Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
CN103130734A (zh) * 2011-12-01 2013-06-05 上海药明康德新药开发有限公司 一种合成1,2-吗啉盐酸盐的方法
CN105695541B (zh) * 2016-03-10 2019-03-15 苏州华赛生物工程技术有限公司 一种抗生素nvp018中间体的分离纯化方法
KR20180036522A (ko) * 2016-09-30 2018-04-09 (주)나노믹스 스틸벤 유도체 및 그 제조 방법
BR112019009903A2 (pt) 2016-11-18 2019-08-13 Neurovive Pharmaceutical Ab análogo de sangliferina, combinação, composição farmacêutica, e, método para tratamento de um sujeito sofrendo de câncer ou de malignidade de célula-b
CN112410353B (zh) * 2019-08-23 2023-01-24 上海医药工业研究院 一种fkbS基因、含其的基因工程菌及其制备方法和用途
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
JP2008546708A (ja) * 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Hcvにおけるサングリフェリンの使用
WO2008084368A2 (en) 2007-01-04 2008-07-17 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
ES2556211T3 (es) 2008-09-24 2016-01-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Agrupación de genes novedosa
CN101691575B (zh) * 2008-09-24 2013-06-05 中国科学院上海有机化学研究所 一种萨菲菌素的生物合成基因簇
WO2011098808A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
BR112012019866A8 (pt) * 2010-02-09 2017-12-26 Biotica Tech Limited Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
JP6086869B2 (ja) * 2010-12-20 2017-03-08 ネウロビベ プハルマセウトイカル エービー サングリフェリン誘導体及びそれらの製造方法
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Also Published As

Publication number Publication date
PL2691413T3 (pl) 2015-05-29
BR112013024965A2 (pt) 2017-04-18
US9139613B2 (en) 2015-09-22
IL228509A0 (en) 2013-12-31
CN103635484A (zh) 2014-03-12
AU2012235961B2 (en) 2016-09-01
CY1116186T1 (el) 2017-02-08
CN103635484B (zh) 2017-05-10
KR20140057481A (ko) 2014-05-13
MY170618A (en) 2019-08-21
PT2691412E (pt) 2015-03-25
JO3063B1 (ar) 2017-03-15
WO2012131371A1 (en) 2012-10-04
EA023907B1 (ru) 2016-07-29
EA201391399A1 (ru) 2014-02-28
CA2830827C (en) 2020-03-10
MX345352B (es) 2017-01-26
IL228509B (en) 2018-02-28
SG193568A1 (en) 2013-11-29
AU2012235880B2 (en) 2016-11-17
DK2691412T3 (en) 2015-04-07
ES2533437T3 (es) 2015-04-10
TW201300398A (zh) 2013-01-01
KR20140071958A (ko) 2014-06-12
AU2012235880A1 (en) 2013-10-17
HK1189237A1 (en) 2014-05-30
SI2691412T1 (sl) 2015-05-29
BR112013024974A2 (pt) 2016-09-06
IL228508A0 (en) 2013-12-31
KR101868084B1 (ko) 2018-06-18
EP2691413A1 (en) 2014-02-05
EP2691412B1 (en) 2014-12-24
AU2012235961A1 (en) 2013-10-10
UY33993A (es) 2012-10-31
CL2013002739A1 (es) 2014-07-11
PT2691413E (pt) 2015-03-25
CN103619869A (zh) 2014-03-05
CN103619869B (zh) 2015-11-25
HRP20150187T1 (en) 2015-06-05
CA2830827A1 (en) 2012-10-04
MX2013011043A (es) 2014-04-25
CN107417766A (zh) 2017-12-01
US9090657B2 (en) 2015-07-28
CY1116318T1 (el) 2017-02-08
RS53963B1 (en) 2015-08-31
JP2014514290A (ja) 2014-06-19
MX2013011051A (es) 2014-03-13
PL2691412T3 (pl) 2015-08-31
JP2014510746A (ja) 2014-05-01
EP2691413B1 (en) 2014-12-24
MX345351B (es) 2017-01-26
TWI525098B (zh) 2016-03-11
US20140038885A1 (en) 2014-02-06
JP6118792B2 (ja) 2017-04-26
CA2830831A1 (en) 2012-10-04
HK1189236A1 (en) 2014-05-30
ZA201307149B (en) 2015-04-29
US20120251581A1 (en) 2012-10-04
RS53964B1 (en) 2015-08-31
SG193569A1 (en) 2013-11-29
JP6118793B2 (ja) 2017-04-26
ES2533438T3 (es) 2015-04-10
CA2830831C (en) 2020-03-10
HRP20150184T1 (hr) 2015-05-08
ZA201307231B (en) 2015-05-27
EA201391396A1 (ru) 2014-02-28
CL2013002740A1 (es) 2014-07-11
IL228508B (en) 2018-01-31
MY170637A (en) 2019-08-21
DK2691413T3 (en) 2015-04-07
SI2691413T1 (sl) 2015-05-29
WO2012131377A1 (en) 2012-10-04
EA023848B1 (ru) 2016-07-29
KR101911484B1 (ko) 2018-10-24
EP2691412A1 (en) 2014-02-05

Similar Documents

Publication Publication Date Title
AR085724A1 (es) ANALOGO DE LA SANGLIFERINA CON ACTIVIDAD INHIBIDORA DE mPTP
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
NI201500128A (es) 3- pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
DOP2012000243A (es) Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales
DOP2016000017A (es) Nuevos compuestos tricíclicos
GT201500348A (es) Compuestos de pirimidinodiona contra estados cardíacos
CR20150183A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CU24335B1 (es) Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
PA8740901A1 (es) Compuestos organicos
ECSP12012103A (es) Inhibidores de virus flaviviridae.
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
NI201400026A (es) 3 - pirimidin - 4 - il - oxazolidin - 2 - onas como inhibidores de la idh mutante.
PE20150887A1 (es) Compuestos de benceno sustituidos
CR20130023A (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
ECSP13012418A (es) Derivados de ácido 2-quinolin-acético como compuestos antivirales para vih
CO6290687A2 (es) Inhibidores de cinasa pim y metodos para su uso
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CO6612228A2 (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
ECSP11011420A (es) Procedimientos para mejorar la farmacocinética
UY31803A (es) Compuesto cristalino
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
CO6781541A2 (es) Derivados glucósidos y usos de los mismos
BR112014008555A2 (pt) r(+)-n-formil-propargil-aminoindano

Legal Events

Date Code Title Description
FB Suspension of granting procedure